U.S. market Open. Closes in 2 hours 26 minutes

GOVXW | GeoVax Labs, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 0.1266 - 0.1266
52 Week Range 0.1266 - 0.1266
Beta N/A
Implied Volatility N/A
IV Rank N/A
Day's Volume 200
Average Volume N/A
Shares Outstanding 190,808,364
Market Cap 27,458,746
Sector Healthcare
Industry Biotechnology
IPO Date N/A
Valuation
Profitability
Growth
Health
P/E Ratio N/A
Forward P/E Ratio N/A
EPS N/A
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 17
Country USA
Website GOVXW
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is also developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; GEO-EM01 for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. GeoVax Labs, Inc. has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.
*Chart delayed
Analyzing fundamentals for GOVXW we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see GOVXW Fundamentals page.

Watching at GOVXW technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, but short-term trend is bullish. More technicals details can be found on GOVXW Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙